Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation

Keni Gu, Dennis D. Weisenburger, Kai Fu, Wing C. Chan, Timothy Charles Greiner, Patricia Aoun, Lynette M Smith, Martin Bast, Zhongfen Liu, Robert G Bociek, Philip Jay Bierman, James Olen Armitage, Julie Marie Vose

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantation (AHSCT). We identified 62 patients with DLBCL who either had an initial complete remission (17 patients) or received salvage chemotherapy for relapsed or refractory disease (45 patients), followed by AHSCT. Tissue microarrays were immunostained with monoclonal antibodies against GCET1, CD10, BCL6, MUM1, FOXP1 and LMO2. Using the Hans algorithm, we classified 50% of the cases as GCB type, whereas the Choi algorithm classified 58% as GCB type and LMO2 was positive in 69%. However, no significant differences were found in the 5-year overall or event-free survivals using any of these approaches. In conclusion, cell of origin fails to predict survival of DLBCL patients treated with AHSCT.

Original languageEnglish (US)
Pages (from-to)143-149
Number of pages7
JournalHematological Oncology
Volume30
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Hematopoietic Stem Cell Transplantation
Germinal Center
B-Lymphocytes
Survival
Disease-Free Survival
Monoclonal Antibodies
Drug Therapy

Keywords

  • Algorithm
  • Autologous hematopoietic stem cell transplantation
  • Cell of origin
  • Diffuse large B-cell lymphoma
  • Immunophenotype
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{0fef7c8ee8a7495e8eb0c958b702592c,
title = "Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation",
abstract = "Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantation (AHSCT). We identified 62 patients with DLBCL who either had an initial complete remission (17 patients) or received salvage chemotherapy for relapsed or refractory disease (45 patients), followed by AHSCT. Tissue microarrays were immunostained with monoclonal antibodies against GCET1, CD10, BCL6, MUM1, FOXP1 and LMO2. Using the Hans algorithm, we classified 50{\%} of the cases as GCB type, whereas the Choi algorithm classified 58{\%} as GCB type and LMO2 was positive in 69{\%}. However, no significant differences were found in the 5-year overall or event-free survivals using any of these approaches. In conclusion, cell of origin fails to predict survival of DLBCL patients treated with AHSCT.",
keywords = "Algorithm, Autologous hematopoietic stem cell transplantation, Cell of origin, Diffuse large B-cell lymphoma, Immunophenotype, Survival",
author = "Keni Gu and Weisenburger, {Dennis D.} and Kai Fu and Chan, {Wing C.} and Greiner, {Timothy Charles} and Patricia Aoun and Smith, {Lynette M} and Martin Bast and Zhongfen Liu and Bociek, {Robert G} and Bierman, {Philip Jay} and Armitage, {James Olen} and Vose, {Julie Marie}",
year = "2012",
month = "9",
day = "1",
doi = "10.1002/hon.1017",
language = "English (US)",
volume = "30",
pages = "143--149",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation

AU - Gu, Keni

AU - Weisenburger, Dennis D.

AU - Fu, Kai

AU - Chan, Wing C.

AU - Greiner, Timothy Charles

AU - Aoun, Patricia

AU - Smith, Lynette M

AU - Bast, Martin

AU - Liu, Zhongfen

AU - Bociek, Robert G

AU - Bierman, Philip Jay

AU - Armitage, James Olen

AU - Vose, Julie Marie

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantation (AHSCT). We identified 62 patients with DLBCL who either had an initial complete remission (17 patients) or received salvage chemotherapy for relapsed or refractory disease (45 patients), followed by AHSCT. Tissue microarrays were immunostained with monoclonal antibodies against GCET1, CD10, BCL6, MUM1, FOXP1 and LMO2. Using the Hans algorithm, we classified 50% of the cases as GCB type, whereas the Choi algorithm classified 58% as GCB type and LMO2 was positive in 69%. However, no significant differences were found in the 5-year overall or event-free survivals using any of these approaches. In conclusion, cell of origin fails to predict survival of DLBCL patients treated with AHSCT.

AB - Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantation (AHSCT). We identified 62 patients with DLBCL who either had an initial complete remission (17 patients) or received salvage chemotherapy for relapsed or refractory disease (45 patients), followed by AHSCT. Tissue microarrays were immunostained with monoclonal antibodies against GCET1, CD10, BCL6, MUM1, FOXP1 and LMO2. Using the Hans algorithm, we classified 50% of the cases as GCB type, whereas the Choi algorithm classified 58% as GCB type and LMO2 was positive in 69%. However, no significant differences were found in the 5-year overall or event-free survivals using any of these approaches. In conclusion, cell of origin fails to predict survival of DLBCL patients treated with AHSCT.

KW - Algorithm

KW - Autologous hematopoietic stem cell transplantation

KW - Cell of origin

KW - Diffuse large B-cell lymphoma

KW - Immunophenotype

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84866292172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866292172&partnerID=8YFLogxK

U2 - 10.1002/hon.1017

DO - 10.1002/hon.1017

M3 - Article

VL - 30

SP - 143

EP - 149

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -